Hims, Novo Nordisk Bound by Mutual Necessity -- Market Talk
Dow Jones
Mar 09
0936 ET - The new partnership between Hims & Hers Health and Novo Nordisk reflects the dependence each company has on the other, say Truist analysts. "The rapid cycle of litigation followed by reconciliation underscores that, while both parties lack trust, they remain bound by mutual necessity," the analysts say. Novo will benefit from Hims' direct-to-consumer channel, helping it to counter Eli Lilly's growing GLP-1 share, while Hims needed to offer legitimate, branded GLP-1s to offset declining GLP-1 compounding revenue. The partnership is only likely to hold "as long as commercial incentives remain aligned," the analysts say. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
March 09, 2026 09:37 ET (13:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.